AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

[1]  L. Pasqualucci,et al.  Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma , 2016, Leukemia.

[2]  C. Arteaga,et al.  The PI3K/AKT Pathway as a Target for Cancer Treatment. , 2016, Annual review of medicine.

[3]  A. Hague,et al.  The PI3K/Akt Pathway in Tumors of Endocrine Tissues , 2016, Front. Endocrinol..

[4]  W. Choi,et al.  Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2015, Modern Pathology.

[5]  H. Rodemann,et al.  Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. , 2015, Seminars in cancer biology.

[6]  W. Choi,et al.  Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions , 2015, Modern Pathology.

[7]  N. Hay,et al.  Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration. , 2015, Cell reports.

[8]  W. Choi,et al.  Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.

[9]  Jui-Hung Hung,et al.  Mir-17∼92 Governs Motor Neuron Subtype Survival by Mediating Nuclear PTEN. , 2015, Cell reports.

[10]  F. Khuri,et al.  mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation , 2015, Molecular and Cellular Biology.

[11]  C. Baldus,et al.  Outlook on PI3K/AKT/mTOR inhibition in acute leukemia , 2015, Molecular and Cellular Therapies.

[12]  Martin O. Leach,et al.  Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers , 2014, Clinical Cancer Research.

[13]  Ying Yan,et al.  Radiation-induced signaling pathways that promote cancer cell survival (Review) , 2014, International journal of oncology.

[14]  W. Choi,et al.  Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.

[15]  D. Olive,et al.  Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies , 2014, mAbs.

[16]  S. Tsuzuki,et al.  Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model , 2014, Leukemia.

[17]  K. Baggerly,et al.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia , 2014, Clinical Cancer Research.

[18]  G. Lenz,et al.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[19]  P. Reddanna,et al.  The Paradox of Akt-mTOR Interactions , 2013, Front. Oncol..

[20]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[21]  W. Choi,et al.  Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study , 2013, Haematologica.

[22]  Y. Akao,et al.  Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. , 2013, Cancer letters.

[23]  A. Martelli,et al.  The emerging multiple roles of nuclear Akt. , 2012, Biochimica et biophysica acta.

[24]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[25]  J. McCubrey,et al.  Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia , 2012, Leukemia.

[26]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[27]  G. Mills,et al.  Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer , 2012, Clinical Cancer Research.

[28]  J. Sparano,et al.  Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma , 2012, Clinical Cancer Research.

[29]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Davies.  Regulation, role, and targeting of Akt in cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Medeiros,et al.  Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. , 2011, Blood.

[32]  H. Nilsson‐Ehle,et al.  High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy , 2010, British journal of haematology.

[33]  J. Testa,et al.  GSK690693 Delays Tumor Onset and Progression in Genetically Defined Mouse Models Expressing Activated Akt , 2010, Clinical Cancer Research.

[34]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[35]  Ling Zhao,et al.  The Phosphatidylinositol 3‐Kinase/Akt Pathway Negatively Regulates Nod2‐Mediated NF‐kappaB Pathway , 2008, Biochemical pharmacology.

[36]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[37]  F. Al-Dayel,et al.  PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma , 2007, Leukemia.

[38]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[39]  B. Bonavida,et al.  ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ , 2007, Oncogene.

[40]  N. Hay,et al.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.

[41]  E. Jaffe,et al.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.

[42]  K. Al-Kuraya,et al.  Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.

[43]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Ying Qi,et al.  Phosphorylation by Glycogen Synthase Kinase-3 Controls c-Myc Proteolysis and Subnuclear Localization* , 2003, Journal of Biological Chemistry.

[45]  C. Sugimoto,et al.  PI3K/Akt and apoptosis: size matters , 2003, Oncogene.

[46]  J. Cheong,et al.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.

[47]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[48]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[49]  Y. S. Kim,et al.  The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  W. Choi,et al.  Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP , 2014, Modern Pathology.

[51]  L. Staudt,et al.  The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.

[52]  Oliver Hoffmann,et al.  Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases , 2004, Modern Pathology.

[53]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.